TuHURA Biosciences (HURA) vs Spruce Biosciences (SPRB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Spruce Biosciences (SPRB) over the past year, losing 24.0% versus a loss of 74.9%. Over five years, SPRB leads with a -99.8% price change compared with -99.9% for HURA. Spruce Biosciences is the larger company by market cap ($126.6 million vs $124.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | SPRB |
|---|---|---|
| Share price | $1.96 | $44.05 |
| Market cap | $124.90M | $126.60M |
| 1-day change | +1.55% | -3.27% |
| YTD return | +158.92% | -49.43% |
| 1-year return | -24.03% | -74.87% |
| 5-year return | -99.87% | -99.82% |
| Forward P/E | — | 8.85 |
| EPS (TTM) | $-0.54 | $-39.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.43 | $188.25 |
| 52-week low | $0.41 | $40.33 |
| Distance from 52-week high | -42.86% | -76.60% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +310.20% | +235.98% |
| Average volume | 244.46K | 78.08K |
| Shares outstanding | 63.73M | 2.87M |
| Employees | 22 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed SPRB by 50.8 percentage points over the past year.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Spruce Biosciences
SPRB stock →Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
HURA vs SPRB FAQ
Which is bigger, TuHURA Biosciences or Spruce Biosciences?
Spruce Biosciences (SPRB) is larger, with a market capitalization of $126.60M compared with $124.90M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, HURA or SPRB?
HURA returned -24.03% over the past 12 months, compared with -74.87% for SPRB (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and Spruce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.